Status:

RECRUITING

Influence of Brain Oscillation-Dependent TMS on Motor Function

Lead Sponsor:

National Institute of Neurological Disorders and Stroke (NINDS)

Conditions:

Healthy

Stroke

Eligibility:

All Genders

18+ years

Brief Summary

Background: When people have a stroke, they often have difficulty moving their arms and hands. Transcranial magnetic stimulation (TMS) can improve how well people with and without stroke can move the...

Detailed Description

Study Description: We will study if corticospinal excitability, intracortical inhibition and intracortical facilitation vary across different sensorimotor alpha and beta electroencephalography (EEG) ...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Healthy younger adults:
  • Ages 18 years to less than 50 years. (18 to 49)
  • Willingness/ability to provide informed consent.
  • Ability to induce a motor evoked potential in the muscle target of the upper extremity, as evaluated during the TMS Screening.
  • Healthy older adults:
  • Age 50 and over
  • Willingness/ability to provide informed consent.
  • Ability to induce a motor evoked potential in the muscle target of the upper extremity, as evaluated during the TMS Screening.
  • Stroke patients:
  • Age 18 and over.
  • Unilateral or bilateral upper limb paresis with the ability to voluntarily contract a finger, hand, wrist, or elbow muscle in the affected arm(s).
  • Stroke onset \> 6 months prior to participation.
  • Intact M1 sufficient to induce motor evoked potentials in the affected upper extremity following ipsilesional TMS, as evaluated during the TMS Screening.
  • Willingness/ability to provide informed consent.
  • If the investigator feels the individual s capacity to provide informed consent is questionable, the NIH Human Subjects Protection Unit (HSPU) will be requested to determine the individual s ability to consent.
  • EXCLUSION CRITERIA:
  • Healthy younger and older adults:
  • Presence of severe neurological or medical disorder (e.g., Parkinson s disease or multiple sclerosis).
  • History of seizures.
  • Chronic use of antipsychotic drugs (e.g., chlorpromazine or clozapine), tri-cyclic or other anti-depressants, benzodiazepines, or prescription stimulants.
  • TMS contraindications, such as:
  • Pacemaker, implanted pump, stimulator, cochlear implant, or metal objects inside the eye or skull.
  • Diagnosed severe hearing loss.
  • Current pregnancy.
  • Staff from our section.
  • Stroke patients:
  • Presence of severe neurological or medical disorder, other than stroke (e.g., Parkinson s disease or multiple sclerosis).
  • History of brainstem stroke.
  • History of seizures.
  • Chronic use of antipsychotic drugs (e.g., chlorpromazine or clozapine), benzodiazepines, or prescription stimulants.
  • TMS contraindications, such as:
  • Pacemaker, implanted pump, stimulator, cochlear implant, or metal objects inside
  • the eye or skull.
  • --Diagnosed severe hearing loss.
  • Current pregnancy.
  • Staff from our section.

Exclusion

    Key Trial Info

    Start Date :

    September 11 2018

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 31 2026

    Estimated Enrollment :

    114 Patients enrolled

    Trial Details

    Trial ID

    NCT03288220

    Start Date

    September 11 2018

    End Date

    March 31 2026

    Last Update

    October 24 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center

    Bethesda, Maryland, United States, 20892